Discover how intellectual property rights protect exclusive pharmaceutical use and brand names in biotechnology, influencing innovation and market dynamics.
The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...
Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s ...
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback